UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) July 31, 2006
Momenta Pharmaceuticals, Inc.
(Exact Name of
Registrant as Specified in Charter)
|
Delaware |
000-50797 |
04-3561634 |
|
(State or Other
Jurisdiction |
(Commission File Number) |
(IRS Employer |
|
|
|
|
|
675 West Kendall Street, Cambridge, MA |
02142 |
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
|
(617) 491-9700
(Registrant’s
telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 31, 2006, Momenta Pharmaceuticals, Inc. (the “Company”) announced that it had submitted an Investigational New Drug Application to the U.S. Food and Drug Administration to begin a Phase I human clinical study of M118, an anticoagulant designed by the Company to specifically treat acute coronary syndromes.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
MOMENTA PHARMACEUTICALS, INC. |
|||
|
|
|
|
||
|
|
|
|
||
|
|
By: |
|
/s/ Richard P. Shea |
|
|
|
|
|
|
Richard P. Shea |
|
Date: July 31, 2006 |
|
|
|
|
3